India’s first dengue vaccine arrives with a crucial safety caveat
India has approved the dengue vaccine Qdenga, manufactured by Takeda, for use in individuals aged 4-60. While the vaccine covers all four dengue serotypes, clinical trial data has raised specific safety concerns that regulators are monitoring.
Why it matters
The introduction of a dengue vaccine is a significant public health milestone for India, though the safety caveats highlight the complexities of vaccine efficacy across different populations.
India’s drug regulator just approved the country’s first dengue vaccine, Qdenga. It is designed and claimed to protect against the four serotypes of the dengue-causing virus, called DENV-1 to DENV-4. Young children as well as adults (aged 4-60 years), irrespective of whether they have had dengue before, may be vaccinated with Qdenga.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in